UKUK

Euro71m for trans-lational medicine

12.05.2006

Dundee - A new Euro71 million funding package is set to boost medical research in Scotland. The 'Translational Medicine Research Collaboration' aims to bolster Scotland's international standing in medical research and bring lifesaving new drugs to patients more quickly. The deal was announced in New York in early April and involves a partnership between four Scottish universities (Aberdeen, Dundee, Edinburgh and Glasgow), NHS Scotland, Scottish Enterprise and the US-pharma company Wyeth Pharmaceuticals, based in Philadelphia. Wyeth plans to invest an estimated Euro47 million over the first five years, while Scottish Enterprise is providing around Euro24 million. The initiative is set to create 50 jobs at a new laboratory at Dundee University. The number of new jobs may rise to 120 over the course of the next five years. Jack McConnell, Scotland's First Minister, said the partnership was an international first and will benefit the Scottish economy. Scotland has a strong reputation in the life sciences. This viewpoint gained a foothold in February when a leading biotechnology entrepreneur said that Scotland's thriving life sciences sector could attract millions of pounds of research work currently going to the US.

UKUK

02.04.2012

London - The not-for-profit UK Biobank, the most comprehensive health study in Britain, is now accessible to researchers from industry and academia. The resource, which contains some 1,000 pieces of health and lifestyle...

UKUK

21.03.2012

London – The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma,...

UKUK

07.03.2012

Nanopore sequencer Oxford Nanopore Technologies, a UK firm that promises its third-generation technology could theoretically sequence a human genome in 15 minutes, impressed scientists with the first public presentation of its...

UKUK

06.03.2012

GlaxoSmithKline (GSK) is further strengthening its activity in the area of rare diseases. The London-based pharma giant has signed an early-stage deal to develop and commercialise treatments for lysosomal storage disorders...

UKUK

27.02.2012

London/Montreal - Angiochem will collaborate with British pharma trust GlaxoSmithKline (GSK) plc on treatments for lysosomal storage diseases (LSD). London-based GSK will pay $300m, including up to $31.5m in upfront cash and...

UKUK

08.02.2012

London - GlaxoSmithKline re-adjusts its €3.7bn R&D budget. Following a review, three of 38 R&D units will be cut and four new ones installed, the UK drug company said in a statement on 7 Februray. Furthermore, six of the...

UKUK

03.02.2012

London - AstraZeneca tries to shed some weight, anticipating a tough year ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company said in a statement. Research and development operations will be cancelled in...

UKUK

16.01.2012

Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture...

Displaying results 1 to 10 out of 396

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-uk/article/euro71m-for-trans-lational-medicine.html

Stock list

All quotes

TOP

  • NOVACYT (F)4.99 EUR9.67%
  • CELLECTIS (F)14.00 EUR4.56%
  • PHARMING (NL)0.53 EUR3.92%

FLOP

  • PROSENSA (NL)10.48 USD-16.29%
  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%

TOP

  • SANTHERA (CH)72.55 CHF134.0%
  • CELLECTIS (F)14.00 EUR113.1%
  • ADDEX (CH)3.62 CHF57.4%

FLOP

  • THROMBOGENICS (B)8.78 EUR-51.2%
  • MERCK KGAA (D)64.18 EUR-49.5%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.55 CHF3545.7%
  • GW PHARMACEUTICALS (UK)432.00 GBP790.7%
  • PAION (D)2.92 EUR342.4%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.4%
  • CYTOS (CH)0.25 CHF-92.8%
  • THROMBOGENICS (B)8.78 EUR-72.1%

No liability assumed, Date: 08.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

Vilnius (LT)

Life Sciences Baltics